Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials

Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials

Sooyoung Shin,1,2 Yoojin Noh1 1College of Pharmacy, Ajou University, Yeongtong-gu, Suwon, Republic of Korea; 2Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Yeongtong-gu, Suwon, Republic of Korea Background: Several clinical trials have shown an increased ris...

Full description

Bibliographic Details
Main Authors: Shin S, Noh Y
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:Therapeutics and Clinical Risk Management
Subjects:
Breast cancer
Metastatic disease
Bevacizumab
Adverse events
Hypertension
Biomarker
Online Access:https://www.dovepress.com/increased-risk-of-adverse-drug-events-secondary-to-bevacizumab-treatme-peer-reviewed-article-TCRM

Internet

https://www.dovepress.com/increased-risk-of-adverse-drug-events-secondary-to-bevacizumab-treatme-peer-reviewed-article-TCRM

Similar Items